Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

PURPOSE: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma. PATIENTS AND METHODS: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) link...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: King, David M., Albertini, Mark R., Schalch, Heidi, Hank, Jacquelyn A., Gan, Jacek, Surfus, Jean, Mahvi, David, Schiller, Joan H., Warner, Thomas, Kim, KyungMann, Eickhoff, Jens, Kendra, Kari, Reisfeld, Ralph, Gillies, Stephen D., Sondel, Paul
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2004
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2367368/
https://ncbi.nlm.nih.gov/pubmed/15483010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.11.035
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi